Enovis (NYSE:ENOV) Insider Purchases $18,307.50 in Stock

Enovis Corporation (NYSE:ENOV) insider Oliver Engert purchased 750 shares of the firm’s stock in a transaction on Friday, March 6th. The stock was bought at an average cost of $24.41 per share, with a total value of $18,307.50. Following the completion of the purchase, the insider owned 45,640 shares of the company’s stock, valued at approximately $1,114,072.40. This represents a 1.67% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Oliver Engert also recently made the following trade(s):

• On Monday, March 9th, Oliver Engert acquired 1,000 shares of Enovis stock. The shares were bought at an average cost of $23.39 per share, for a total transaction of $23,390.00.
• On Wednesday, March 4th, Oliver Engert bought 250 shares of Enovis stock. The stock was purchased at an average price of $25.10 per share, with a total value of $6,275.00.
• On Tuesday, March 3rd, Oliver Engert purchased 1,000 shares of Enovis stock. The shares were purchased at an average cost of $24.77 per share, for a total transaction of $24,770.00.
• On Friday, February 27th, Oliver Engert acquired 1,000 shares of Enovis stock. The stock was purchased at an average cost of $25.50 per share, with a total value of $25,500.00.

Enovis Stock Down 0.0%

Shares of NYSE ENOV traded down $0.00 during midday trading on Friday, hitting $23.39. 101,593 shares of the stock traded hands, compared to its average volume of 1,122,098. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.04 and a current ratio of 2.02. Enovis Corporation has a one year low of $21.00 and a one year high of $40.69. The business has a 50 day moving average price of $23.87 and a two-hundred day moving average price of $27.88. The company has a market cap of $1.34 billion, a PE ratio of -1.13 and a beta of 1.46.

Enovis (NYSE:ENOV) last posted its quarterly earnings results on Thursday, February 26th. The company reported $0.95 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.81 by $0.14. Enovis had a negative net margin of 52.69% and a positive return on equity of 8.74%. The business had revenue of $575.76 million during the quarter, compared to the consensus estimate of $584.30 million. During the same quarter last year, the firm posted $0.98 EPS. Enovis’s revenue was up 2.6% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, equities analysts predict that Enovis Corporation will post 2.79 EPS for the current year.

Hedge Funds Weigh In On Enovis

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. grew its position in Enovis by 2.0% during the third quarter. Vanguard Group Inc. now owns 6,524,235 shares of the company’s stock valued at $197,945,000 after buying an additional 125,460 shares during the period. Dimensional Fund Advisors LP raised its position in Enovis by 1.8% in the third quarter. Dimensional Fund Advisors LP now owns 2,971,545 shares of the company’s stock worth $90,156,000 after acquiring an additional 51,201 shares during the period. Rubric Capital Management LP purchased a new position in Enovis in the third quarter valued at about $83,435,000. Hood River Capital Management LLC boosted its stake in Enovis by 20.3% in the second quarter. Hood River Capital Management LLC now owns 1,735,533 shares of the company’s stock valued at $54,426,000 after acquiring an additional 292,950 shares during the last quarter. Finally, River Road Asset Management LLC grew its position in shares of Enovis by 3.2% during the 4th quarter. River Road Asset Management LLC now owns 1,487,277 shares of the company’s stock valued at $39,621,000 after acquiring an additional 46,289 shares during the period. 98.45% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Needham & Company LLC raised their price target on shares of Enovis from $49.00 to $52.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Zacks Research raised Enovis from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, March 4th. Evercore restated an “outperform” rating on shares of Enovis in a report on Monday, January 12th. UBS Group reaffirmed a “buy” rating and set a $50.00 target price on shares of Enovis in a research report on Monday, January 5th. Finally, Canaccord Genuity Group lowered their price target on Enovis from $58.00 to $50.00 and set a “buy” rating for the company in a research report on Wednesday, December 17th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Enovis currently has a consensus rating of “Moderate Buy” and an average price target of $47.43.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.